TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer

• Status: Completed
• Trial end date: 2008-07-01

Summary

The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy.

• Phase: Phase 3

Details

• Lead Sponsor: Telik
• Treatments: Carboplatin; Doxorubicin; Liposomal doxorubicin